Overview

An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2026-10-01

Target enrollment:

Participant gender:

Summary

This is a single-arm study evaluating the efficacy and safety of Stapokibart Injection in combination with Tislelizumab Injection in patients with driver gene-negative NSCLC who have failed prior PD-1/PD-L1 inhibitor therapy.

Phase:

PHASE2

Details

Lead Sponsor:

Sichuan University

Treatments:

tislelizumab